Candel Therapeutics, Inc. — Director's Dealing 2021

Aug 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-29

Reporting Person: Martell Christopher (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-29	Common Stock	C	283514	—	Acquired	283514	Indirect
2021-07-29	Common Stock	P	125000	$8.00	Acquired	125000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-29	Series B Preferred Stock	$	C	696851	Disposed		Common Stock (283514)	Indirect

Footnotes

F1: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F2: Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

F3: Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.